Dual antiplatelet therapy (DAPT) with a platelet ADP P2Y12 receptor (P2Y12) inhibitor plus aspirin is critical to prevent major adverse cardiovascular events (MACE) following acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI).1 For patients with ACS, the guidelines recommend DAPT for at least 1 year after PCI.1 Clopidogrel, prasugrel, and ticagrelor are the 3 most prescribed oral P2Y12 inhibitors in the US. The gene discussed is P2RY12; the disease is acute coronary syndrome.